Dried Blood Spot Collection Cards

Global Dried Blood Spot Collection Cards Market to Reach US$468.1 Million by 2030

The global market for Dried Blood Spot Collection Cards estimated at US$387.6 Million in the year 2024, is expected to reach US$468.1 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Whatman 903 Card, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$197.1 Million by the end of the analysis period. Growth in the Ahlstrom 226 Card segment is estimated at 2.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$105.6 Million While China is Forecast to Grow at 6.2% CAGR

The Dried Blood Spot Collection Cards market in the U.S. is estimated at US$105.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.5 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Dried Blood Spot Collection Cards Market – Key Trends & Drivers Summarized

Is the Rising Focus on Remote Diagnostics and Decentralized Testing Throwing the Spotlight on Dried Blood Spot Collection Cards?

As healthcare systems worldwide pivot toward decentralized diagnostics and remote patient monitoring, dried blood spot (DBS) collection cards are gaining significant prominence as a minimally invasive, cost-effective, and highly portable biosampling method. DBS cards, which involve collecting small volumes of capillary blood on specialized filter paper, are increasingly used for diagnostic testing, disease surveillance, and therapeutic drug monitoring in both clinical and research settings. Their utility is particularly evident in resource-limited environments where traditional phlebotomy infrastructure is lacking or where cold-chain logistics are infeasible. From infectious disease testing (like HIV and hepatitis) to newborn screening, metabolic disorder detection, and pharmacokinetics, DBS cards are becoming an essential tool for accessible and scalable diagnostics. The COVID-19 pandemic further accelerated the demand for remote testing tools, placing renewed emphasis on DBS cards as part of home testing kits and public health surveillance initiatives. Their compatibility with mail-in diagnostics and ease of long-term sample storage without refrigeration make them especially useful for biobanking and longitudinal studies. As personalized medicine and epidemiological monitoring become more widespread, DBS collection cards are proving to be an efficient, patient-friendly method of enabling mass-scale testing with minimal infrastructure. This evolving demand landscape is positioning DBS cards as a core technology in the shift from centralized lab testing to decentralized, patient-centric healthcare models.

How Are Technological Improvements Enhancing the Accuracy and Applications of DBS Collection Cards?

Innovations in sample collection materials, analytical sensitivity, and laboratory processing are driving the evolution of dried blood spot collection cards from simple field tools to precision diagnostic platforms. Modern DBS cards are manufactured using high-grade filter papers with uniform absorption, defined spot boundaries, and chemical stability that preserve analyte integrity over extended periods. Coated cards with chemical stabilizers or antimicrobial properties are being developed to support the safe collection and transport of volatile biomarkers, nucleic acids, or viral particles. These advancements have significantly expanded the analytical range of DBS cards, making them suitable not just for basic biomarker detection but also for genetic screening, molecular diagnostics, and next-generation sequencing (NGS) workflows. Automated punching systems and robotic sample handlers are reducing manual variability in labs, while improved extraction techniques are enabling the recovery of higher-quality analytes from smaller sample volumes. Laboratories can now perform highly sensitive assays—such as LC-MS/MS, ELISA, PCR, and even whole-genome analysis—using samples derived from DBS cards. Digital traceability solutions, including QR codes and cloud-based sample tracking, are also being integrated to enhance sample management and patient-data linkage. These technological upgrades are expanding the utility of DBS cards in clinical trials, drug development, and public health programs, positioning them as powerful tools not only for field diagnostics but also for precision laboratory-based applications.

Is the Expansion of At-Home Testing and Population Screening Boosting Demand for DBS Cards?

The global rise of consumer-directed health testing, at-home diagnostics, and national screening initiatives is creating fertile ground for the expansion of dried blood spot collection card usage. Consumers today are more willing to participate in health monitoring outside traditional clinical settings, driven by convenience, privacy, and the digital health ecosystem’s rapid growth. At-home testing services—offering everything from cholesterol checks to food sensitivity panels and hormone level assessments—are increasingly adopting DBS collection kits for their simplicity and mail-ready format. National health agencies and NGOs are also leveraging DBS-based collection methods in large-scale population health studies, newborn screening programs, vaccination response monitoring, and epidemiological surveillance. The cards’ ability to retain sample integrity over time and under variable storage conditions makes them highly suitable for use in rural or underserved populations where medical infrastructure is limited. Moreover, in clinical trials and decentralized research models, DBS cards are streamlining participant enrollment and sample logistics by allowing remote collection and centralized analysis. Telemedicine platforms are integrating DBS kits into chronic disease management programs for diabetes, cardiovascular conditions, and HIV, enabling regular monitoring without in-person visits. The rising trust in self-administered diagnostic tools, coupled with advancements in digital health interfaces, is reinforcing the value proposition of DBS cards as critical enablers of accessible, scalable, and patient-driven diagnostics in both developed and emerging markets.

What Are the Key Drivers Fueling Growth in the Dried Blood Spot Collection Cards Market?

The growth in the dried blood spot collection cards market is driven by a combination of technological, clinical, and behavioral factors shaping the future of diagnostics and biosampling. A primary growth driver is the widespread push toward decentralizing healthcare services, particularly in light of lessons learned during the COVID-19 pandemic, which highlighted the value of remote, low-contact diagnostic tools. Rising prevalence of chronic and infectious diseases is prompting broader use of DBS cards for regular monitoring and screening, especially in resource-constrained settings where access to phlebotomy is limited. The expansion of genetic and molecular testing is also increasing demand for high-quality biospecimens that can be collected easily and stored long-term without specialized refrigeration or transport systems. Government support for public health surveillance, maternal and child health programs, and national biobanking efforts is creating a robust institutional demand base for DBS collection systems. The growing popularity of direct-to-consumer health testing and personalized medicine is fueling adoption by private diagnostic firms and wellness platforms. Additionally, the reduced cost of collection, storage, and shipment relative to traditional blood draws makes DBS cards economically attractive for both clinical and research applications. Regulatory bodies in multiple regions are increasingly recognizing DBS as a valid specimen format for diagnostic and pharmacological use, further legitimizing its role in healthcare workflows. Together, these factors are accelerating the global adoption of DBS collection cards and establishing them as an essential tool in the future of decentralized and preventive healthcare.

SCOPE OF STUDY:

The report analyzes the Dried Blood Spot Collection Cards market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Card Type (Whatman 903 Card, Ahlstrom 226 Card, FTA Card, Other Card Types); Application (New Born Screening Application, Infectious Diseases Testing Application, Therapeutic Drug Monitoring Application, Forensics Application, CRO / Research Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostics Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Ahlstrom-Munksjö
• ARCHIMEDlife
• CENTOGENE N.V.
• Eastern Business Forms, Inc.
• F. Hoffmann-La Roche Ltd
• Gentegra LLC
• Hemaxis
• LaCAR MDx
• Lipomic Healthcare
• Metabolon
• Neoteryx
• PerkinElmer
• QIAGEN
• RDA Spot
• Shimadzu Scientific Instruments
• Synergy Medical Systems LLP
• Thomas Scientific
• Trajan Scientific Australia Pty Ltd
• Whatman

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.